BioSpace News Archive

Business

Mirati Therapeutics Appoints David Meek as Chief Executive Officer

Mirati Therapeutics, Inc. today announced the appointment of David Meek as Chief Executive Officer (CEO), effective immediately

September 20, 2021
·
5 min read
Pharm Country

VYNE Therapeutics to Present at the Cantor Fitzgerald Investment Conference

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference, to take place September 27th – 30th.

September 20, 2021
·
2 min read
Compression Therapy Devices Market: Rising prevalence of vascular diseases to drive the market

Products in the global compression therapy devices market are utilized for the treatment of various chronic diseases including lymphedema, phlebitis, leg ulcers, and thrombosis along with other forms of varicose veins.

September 20, 2021
·
6 min read
COVID-19 Antigen Test Market: In-depth Insights, Revenue Details, Regional Analysis by 2031

Evolution of new strains of the SARS-CoV-2 virus along with increasing spikes in the instances of new COVID-19 infections are stimulating the demand in the global COVID-19 antigen test market over the forecast period.

September 20, 2021
·
5 min read
Drug Development

OSE Immunotherapeutics To Present Positive Results of Tedopi® Phase 3 Clinical Trial in Non-Small Cell Lung Cancer Patients in Secondary Resistance to Immune Checkpoint Inhibitors At the ESMO Virtual Congress 2021

OSE Immunotherapeutics announces the presentation of Phase 3 clinical results of Tedopi® at 13:30 CEST in a late-breaking oral presentation at the European Society for Medical Oncology Virtual Congress.

September 20, 2021
·
5 min read
Genetown

Annexon Biosciences to Highlight Neurodegeneration Franchise in Upcoming Virtual C1q Series R&D Event

Annexon, Inc. announced that the company will host its second virtual C1q Series event on Monday, September 27, 2021, at 10:00 a.m. ET, to discuss its neurodegeneration franchise.

September 20, 2021
·
1 min read
Drug Development

Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria

Synlogic, Inc., a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced positive data from clinical studies evaluating both SYNB1618 and SYNB1934, investigational Synthetic Biotic™ medicines for the treatment of phenylketonuria.

September 20, 2021
·
9 min read
Drug Development

Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial

Immunocore Holdings Plc presented new data from the Company’s lead program, tebentafusp, at an oral presentation at the European Society for Medical Oncology Congress.

September 20, 2021
·
7 min read
Business

Matinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors

Matinas BioPharma Holdings, Inc. announced the nomination of Kathryn Penkus Corzo to stand for election to the Company’s Board of Directors at its 2021 Annual Meeting of Stockholders, scheduled for November 1, 2021.

September 20, 2021
·
9 min read
Drug Development

Algernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil Chronic Cough Study in the U.S.

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to announce that it plans to file a pre-IND meeting request with the U.S. Food and Drug Administration for an NP-120 Phase 2 chronic cough study.

September 20, 2021
·
5 min read